Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial

To evaluate the safety of the 15-valent pneumococcal conjugate vaccine (PCV15 (by LvZhu & Co. Ltd)) in healthy infants aged 2 months (minimum to 6 weeks) and 3 months old. This phase I clinical trial enrolled 80 subjects in Laishui County, Hebei Province, China. The total population was divided...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Lu-Lu, Gao, Zhao, Zhou, Wei-Wei, Li, Min-Jie, Fang, Wen-Jian, Ji, Wen-Juan, Zhao, Ying, Du, Lin, Zhao, Yu-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Pneumococcal – Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746401/
https://www.ncbi.nlm.nih.gov/pubmed/36121914
http://dx.doi.org/10.1080/21645515.2022.2116881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746401/
https://www.ncbi.nlm.nih.gov/pubmed/36121914
http://dx.doi.org/10.1080/21645515.2022.2116881

Ejemplares similares